Ruzzene M - Search Results

1

Targeting CK2 in cancer: a valuable strategy or a waste of time?

Salvi M, Borgo C, Pinna LA, Ruzzene M. Salvi M, et al. Among authors: ruzzene m. Cell Death Discov. 2021 Oct 29;7(1):325. doi: 10.1038/s41420-021-00717-4. Cell Death Discov. 2021. PMID: 34716311 Free PMC article. Review.

2

Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. Borgo C, et al. Among authors: ruzzene m. Signal Transduct Target Ther. 2021 May 17;6(1):183. doi: 10.1038/s41392-021-00567-7. Signal Transduct Target Ther. 2021. PMID: 33994545 Free PMC article. Review.

3

Protein kinase CK2 inhibition as a pharmacological strategy.

Borgo C, Ruzzene M. Borgo C, et al. Among authors: ruzzene m. Adv Protein Chem Struct Biol. 2021;124:23-46. doi: 10.1016/bs.apcsb.2020.09.003. Epub 2021 Jan 9. Adv Protein Chem Struct Biol. 2021. PMID: 33632467 Review.

4

Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis.

Di Maira G, Brustolon F, Tosoni K, Belli S, Krämer SD, Pinna LA, Ruzzene M. Di Maira G, et al. Among authors: ruzzene m. Mol Cell Biochem. 2008 Sep;316(1-2):155-61. doi: 10.1007/s11010-008-9813-6. Epub 2008 Jun 17. Mol Cell Biochem. 2008. PMID: 18560764

5

Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

Ruzzene M, Pinna LA. Ruzzene M, et al. Biochim Biophys Acta. 2010 Mar;1804(3):499-504. doi: 10.1016/j.bbapap.2009.07.018. Epub 2009 Aug 6. Biochim Biophys Acta. 2010. PMID: 19665589 Review.

6

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, Ruzzene M. Zanin S, et al. Among authors: ruzzene m. PLoS One. 2012;7(11):e49193. doi: 10.1371/journal.pone.0049193. Epub 2012 Nov 8. PLoS One. 2012. PMID: 23145120 Free PMC article.

7

Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.

Cozza G, Sarno S, Ruzzene M, Girardi C, Orzeszko A, Kazimierczuk Z, Zagotto G, Bonaiuto E, Di Paolo ML, Pinna LA. Cozza G, et al. Among authors: ruzzene m. Biochim Biophys Acta. 2013 Jul;1834(7):1402-9. doi: 10.1016/j.bbapap.2013.01.018. Epub 2013 Jan 27. Biochim Biophys Acta. 2013. PMID: 23360763

8

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A. Borgo C, et al. Among authors: ruzzene m. Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22. Mol Oncol. 2013. PMID: 24012109 Free PMC article.

9

Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Cozza G, Girardi C, Ranchio A, Lolli G, Sarno S, Orzeszko A, Kazimierczuk Z, Battistutta R, Ruzzene M, Pinna LA. Cozza G, et al. Among authors: ruzzene m. Cell Mol Life Sci. 2014 Aug;71(16):3173-85. doi: 10.1007/s00018-013-1552-5. Epub 2014 Jan 18. Cell Mol Life Sci. 2014. PMID: 24442476 Free PMC article.

10

Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions.

Girardi C, James P, Zanin S, Pinna LA, Ruzzene M. Girardi C, et al. Among authors: ruzzene m. Biochim Biophys Acta. 2014 Sep;1843(9):1865-74. doi: 10.1016/j.bbamcr.2014.04.020. Epub 2014 Apr 24. Biochim Biophys Acta. 2014. PMID: 24769357 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page